Please assess the completion status of the following clinical trial:

Trial Title: A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥ 18 years.~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1~* Expected survival ≥ 6 months.~* Histologically or cytologically confirmed local advanced/metastatic pancreas adenocarcinoma.~* Documented mutation in germline BRCA1/2 or PALB2 that is predicted to be deleterious or suspected deleterious.~* Adequate organ performance based on laboratory blood tests.~* Presence of at least of one measurable lesion in agreement to RECIST criteria.~* Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.~* Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* Patients who have received any chemotherapy for the treatment of pancreatic cancer prior to entering the study.~* Previous treatment with any poly ADP-ribose polymerase (PARP) inhibitor.~* Patients who have had radiotherapy or participated in another clinical trial with any investigational agents within 28 days of enrolment (Day 1 visit).~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to oxaliplatin, irinotecan, 5-Fluorouracil or other agents used in the study.~* Previous treatment using CYP3A4 inducers within 3 weeks or inhibitors within 2 weeks of enrolment (Day 1 visit).~* Patients with known or suspected brain metastasis.~* Significant cardiovascular disease such as New York Heart Associate Class III/IV, cardiac failure, myocardial infarction, unstable arrhythmia, or evidence of ischemia on ECG within 6 months prior to enrolment.~* Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.~* Patients with myelodysplastic syndrome/acute myeloid leukaemia.~* Patients with second primary cancer except curatively treated in-situ cancer or slowly progressing malignancy.~* Known active hepatitis B or C infection.~* History of immunodeficiency (including HIV infection) or organ transplantation.~* Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluzoparib+mFOLFIRINOX (Type: EXPERIMENTAL): Fluzoparib+mFOLFIRINOX followed by Fluzoparib maintenance monotherapy
- Placebo+mFOLFIRINOX (Type: PLACEBO_COMPARATOR): Placebo+mFOLFIRINOX followed by placebo maintenance monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).